Ibrutinib Is Effective In Relapsed Or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results From A Prospective Phase Ii Study

Background Relapsed or refractory (R/R) transformed indolent B-cell non-Hodgkin lymphoma (iB-NHL) is associated with a poor prognosis. Unfortunately, there is little prospective data using novel agents, including kinase inhibitors, since trials tend to specifically exclude transformed disease. To address this question we evaluated single agent ibrutinib in patients with R/R transformed iB-NHL.